title: First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
abstract: The patient reported outcomes measurement information system (PROMIS) provides clinicians and researchers access to reliable, validated measures of physical, mental, and social well-being. The use of PROMIS can facilitate comparisons among clinical subpopulations and with the U.S. general population. We report on the first study using PROMIS measures in patients with neurofibromatosis (NF). Eighty-six adult patients (mean age = 44; 55% female; 87% white; 50% NF1, 41% NF2 and 9% schwannomatosis) completed a battery of PROMIS computerized adaptive tests (CATs). Across all PROMIS instruments, mean scores for each CAT were between 48.97 and 52.60, which is within ±0.5 SD of the U.S. general population norms. However, scores were distributed across a broad range for each PROMIS measure (±3 SDs). Clinically meaningful scores (defined >1 SD impairment) were observed in 20% (pain interference), 17% (pain behavior), 16% (physical function), 16% (anxiety), 16% (depression), 15% (satisfaction with social roles), 13% (fatigue), 6% (anger), and 5% (satisfaction with discretionary social activities) of the sample. All PROMIS measures were highly interrelated in bivariate analysis (P ≤ .001). There were no differences in PROMIS scores by disease type (NF1, NF2 and schwannomatosis), or self reported learning disabilities, or compared with the US population. Scores suggest a broad continuum of symptoms and functioning in patients with NF that is not affected by NF type, as well as interrelation among the physical and psychosocial domains as measured by PROMIS. PROMIS measures may be useful in clinical practice to monitor changes in symptoms and functioning over time, as well as in clinical trials to determine patient reported changes during drug and psychosocial clinical trials.
authors.affiliation: Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Talaei-Khoei
authors.affiliation: Department of Psychiatry, Benson-Henry Institute of Mind Body Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Riklin
authors.affiliation: Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Vanessa L
authors.initials: VL
authors.lastname: Merker
authors.affiliation: Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Monica R
authors.initials: MR
authors.lastname: Sheridan
authors.affiliation: Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Justin T
authors.initials: JT
authors.lastname: Jordan
authors.affiliation: Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Scott R
authors.initials: SR
authors.lastname: Plotkin
authors.affiliation: Department of Psychiatry, Behavioral Medicine Service, Massachusetts General Hospital, Harvard Medical School, One Bowdoin Square, 7th Floor, Boston, MA, 02114, USA. avranceanu@mgh.harvard.edu.
authors.forename: Ana-Maria
authors.identifier: 0000-0003-3994-6488
authors.initials: AM
authors.lastname: Vranceanu
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009442:Neurilemmoma / Q000175:diagnosis / Q000523:psychology; D017253:Neurofibromatoses / Q000175:diagnosis* / Q000523:psychology; D009456:Neurofibromatosis 1 / Q000175:diagnosis / Q000523:psychology; D016518:Neurofibromatosis 2 / Q000175:diagnosis / Q000523:psychology; D000071066:Patient Reported Outcome Measures; D012878:Skin Neoplasms / Q000175:diagnosis / Q000523:psychology
keywords: Neurofibromatosis; PROMIS; Physical; Psychological; Social